Study of pancreatic tumors in people with VHL
Part of Brain & nervous system, Cancer, Digestive system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This trial studies the natural course and management of pancreatic neuroendocrine tumors in people with von Hippel–Lindau (VHL) disease. It may help doctors better predict how these pancreatic findings change over time and how to manage them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with VHL by genetic testing showing a VHL gene change, or by VHL clinical diagnosis.
- You have at least one pancreatic finding seen on a non-invasive scan (like cysts or solid spots that look like certain VHL-related tumor types).
- You are age 12 or older.
- You can understand the study and are willing to sign an informed consent form (and assent if applicable).
- You must be able to do repeated non-invasive imaging over time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at the health records of children with Von Hippel-Lindau disease to understand how the condition progresses and to find factors that predict long-term outcomes. It focuses on hemangioblastomas in the brain and spinal cord, which are non-cancerous tumors.
This study looks at how early changes in kidney cells can lead to tumors in people with VHL disease. It may help understand why some people develop kidney cancer and how to prevent it.
This study is for people with von Hippel-Lindau (vHL) disease to collect information for research. It may help researchers better understand the condition and how to care for people with it.
This trial focuses on checking whether a specific inner-ear tumor (called an endolymphatic sac tumor) can be found earlier in people with Von Hippel-Lindau (vHL) disease. It may help doctors detect problems sooner so you can discuss treatment options earlier, if needed.
This study follows people who have von Hippel-Lindau (VHL) over time to better understand how the condition changes. It may help doctors plan future treatments by collecting long-term health information.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
Hear when a new Von Hippel-Lindau Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.